Note sull'episodio
This episode analyses the current landscape of chronic hepatitis B (CHB) clinical guidelines across five major regions—United States (AASLD), Canada (CASL), China, Japan (JSH), and Europe (EASL)—alongside the World Health Organization (WHO) guidelines. The analysis highlights significant variations in treatment thresholds, diagnostic approaches, implementation strategies, and market access opportunities, all of which are critical for pharmaceutical commercialization and strategic planning for CHB therapies.
Key themes include:
- Divergent Treatment Initiation Criteria: China has the most liberal treatment thresholds, aiming for WHO elimination targets by 2030, while other regions maintain more conservative approaches.
- Emphasis on Non-Invasive Assessment: There's a growing trend towards non ...